Código 3004 (Harmonized System 2012 by 4 digits)
2023: US$6.45B, Total Trade Exchange
2023: US$1.79B, International Sales
2023: US$4.67B, International Purchases
In 2023, the trade exchange (includes international purchases and sales) of Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses was US$6.45B.
In 2023, the states with the most international sales in Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses were Ciudad de México (US$1.01B), Estado de México (US$263M), Jalisco (US$203M), Baja California (US$46.4M), and Chihuahua (US$10M).
The states with the most international purchases in 2023 were Ciudad de México (US$3.71B), Estado de México (US$650M), Jalisco (US$113M), Morelos (US$62.6M), and Chihuahua (US$45.7M).
In 2023, the main commercial destinations of Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses were United States (US$495M), Canada (US$193M), Colombia (US$135M), Brazil (US$126M), and Panama (US$105M).
The main commercial origins of Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses in 2023 were Germany (US$862M), United States (US$750M), France (US$342M), Italy (US$302M), and Spain (US$256M).
In the global context, the main exporting countries of Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses in 2022 were Germany (US$73.7B), Switzerland (US$43B), and United States (US$41.4B). In the same year, the main importing countries of Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses were United States (US$88.2B), Germany (US$32.7B), and Switzerland (US$31.7B).
US$6.45B, Total Trade Exchange (2023)
In 2023, the total trade exchange of Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses in Mexico (including international purchases and sales) was US$6.45B.
The visualizations show the net balance of Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
July, 2024
In July 2024, international sales of Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses were US$218M, while international purchases reached US$506M. The above results in a trade balance of -US$288M.
2024-Q3: US$182M, International Sales
The visualization shows the quarterly concentration of international sales of Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses at state level.
In the third quarter of 2024, international sales were US$182M, being the states with the most sales Ciudad de México (US$135M), Jalisco (US$23M), and Estado de México (US$21.9M).
Ciudad de México: US$1.01B, State with the Most International Sales (2023)
United States: US$495M, Main commercial destination (2023)
In 2023, the states with the highest international sales in Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses were Ciudad de México (US$1.01B), Estado de México (US$263M), Jalisco (US$203M), Baja California (US$46.4M), and Chihuahua (US$10M).
In 2023, the countries with the most international purchases from Mexico were United States (US$495M), Canada (US$193M), Colombia (US$135M), Brazil (US$126M), and Panama (US$105M).
Ciudad de México: US$3.71B, State with the Most International Purchases (2023)
Germany: US$862M, Main Commercial Origin (2023)
In 2023, the states with the highest international in Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses were Ciudad de México (US$3.71B), Estado de México (US$650M), Jalisco (US$113M), Morelos (US$62.6M), and Chihuahua (US$45.7M).
The countries with the most international sales to Mexico in 2023 were Germany (US$862M), United States (US$750M), France (US$342M), Italy (US$302M), and Spain (US$256M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses were Germany (US$73.7B), Switzerland (US$43B), and United States (US$41.4B). In the same year, the main importing countries for Medicaments Consisting of Mixed or Unmixed Products, Preparations for Therapeutic or Prophylactic Uses were United States (US$88.2B), Germany (US$32.7B), and Switzerland (US$31.7B).